The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptamer Group Regulatory News (APTA)

Share Price Information for Aptamer Group (APTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.725
Bid: 0.65
Ask: 0.80
Change: -0.025 (-3.33%)
Spread: 0.15 (23.077%)
Open: 0.75
High: 0.75
Low: 0.70
Prev. Close: 0.75
APTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Aptamer and Kairos Biotech partner for Optimer+

18 Apr 2024 07:00

RNS Number : 0493L
Aptamer Group PLC
18 April 2024
 

 

18 April 2024

 

 

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Aptamer and Kairos Biotech partner for Optimer+ transplant rejection therapies

- Partnership will use the new Optimer+ platform

- Optimer+ EM molecules to be developed to help prevent transplant rejection

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the progression of a partnership with Kairos Biotech, an early-stage company developing novel therapeutic solutions for transplant rejection.

 

As part of this agreement, Kairos Biotech will leverage Aptamer's new Optimer®+ affinity ligand platform in development of their pipeline of 'EM' molecules that specifically target pathways involved in transplant rejection. The approach will improve transplant access for difficult to transplant patients and improve the chances of transplant success. Additionally, EM molecules can be used for transplant monitoring and improving pre- and post-transplant diagnostics. These novel treatments are targeting an £800 million transplant diagnostic sector and a potential £2 billion transplant immunotherapy market. 

 

Success in the proof-of-concept project will allow expansion of the collaboration to deliver potentially over a hundred Optimer®+ molecules enabling targeting a greater variety of transplant rejection molecules. There is additional scope for the developed Optimer®+ binders to be used as diagnostic reagents to profile a patient's immune system before treating them with the tailored therapy.

 

Kairos Biotech is one of the first partners to undertake fee-for-service projects using Aptamer's cutting-edge Optimer®+ platform. Adopting this innovative technology to explore potential therapeutic solutions provides Kairos Biotech with access to a new therapeutic modality that can deliver the high affinity and high specificity binders required to meet the complex needs of such large-scale, multi-target therapeutic solutions.

 

Optimer®+ uses a modified oligonucleotide library to create hybrid DNA-peptide binders engineered with a scaffold structure for stability, ease of manufacturing and engineering. The new binders bridge the gap between traditional aptamers and protein-based affinity ligands, combining the flexibility, manufacturing, and stability benefits of its current technology with the functional diversity and binding capability of a protein. 

Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We're delighted to bring our proprietary Optimer®+ platform to support Kairos Biotech in this game-changing theranostic application. Initial animal studies have shown the Optimer®+ binders to be well tolerated for therapeutic approaches, and the exquisite specificity of these binders is ideally suited to such a large-scale diagnostic and therapeutic project. The team at Kairos has an exciting scientific approach to immunosuppression that could offer an improved outlook for transplant patients, and we look forward to working with them to advance this using Optimer®+." 

Dr Mike Bunce, Chief Executive Officer at Kairos Biotech Ltd, said: "We are excited to work with Aptamer Group combining their Optimer®+ platform with our novel bioengineering approaches in transplant diagnostics and targeted immunosuppression. The Optimer®+ platform is expected to deliver real advantages in developing our pipeline of immune targeted molecules which in turn will help improve transplant success in the future.

 

- ENDS - 

For further information, please contact: 

 

Aptamer Group plc 

Steve Hull 

+44 (0) 1904 217 404 

Kairos Biotech Ltd

Mike Bunce 

+44 (0) 7549823564

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam Dawes 

+44 (0) 20 3368 3550 

Turner Pope Investments (TPI) Limited - Broker

James Pope / Andrew Thacker 

+44 (0) 20 3657 0050 

 

About Aptamer Group plc 

Aptamer Groupdevelops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers. 

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.

 

About Kairos Biotech Ltd 

 

Kairos Biotech is a North Wales early-stage company developing a pipeline of small molecules for next generation immunotherapy and diagnostics. The company aims to improve transplant options and help remove barriers to transplantation with novel diagnostic and immunotherapy applications. 

Kairos Biotech is founded and funded by transplant diagnostics pioneers with a track record of developing transplant diagnostics over the last thirty years. EchiumBio Holding B.V., a private holding of Wietse Mulder PhD is the major source of funding for Kairos Biotech.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBDLLFZZLEBBX
12
Date   Source Headline
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20248:45 amRNSHolding(s) in Company
23rd Apr 20242:03 pmRNSHolding(s) in Company - REPLACEMENT
22nd Apr 20244:37 pmRNSHolding(s) in Company
22nd Apr 20247:00 amRNSTop Pharma Company evaluates Optimer for medicine
18th Apr 202410:06 amRNSTR-1: Notification of major holdings
18th Apr 20247:00 amRNSAptamer and Kairos Biotech partner for Optimer+
8th Apr 20247:00 amRNSPatent submission for Optimer® binders
28th Mar 20242:07 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSInterim Results
22nd Mar 20247:00 amRNSNotice of Interim Results & Investor Presentation
14th Mar 20247:00 amRNSInvestor Webinar
11th Mar 20247:00 amRNSAptamer Progresses Partnership with Unilever
29th Feb 20247:00 amRNSBlock Listing Interim Review
27th Feb 20247:00 amRNSR&D progress on new Optimer®+ platform
22nd Feb 20247:00 amRNSSecond Phase of Alzheimer's test with Neuro-Bio
5th Feb 20247:00 amRNSHalf Year Trading Update
4th Jan 20242:39 pmRNSHolding(s) in Company
15th Dec 20233:57 pmRNSResults of 2023 Annual General Meeting
15th Dec 20237:00 amRNSAGM Statement
14th Dec 20237:00 amRNSMaterial Agreement with Genetic Medicines Company
20th Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20237:00 amRNSFull year results for the 12mths ended 30 Jun 2023
8th Nov 202312:20 pmRNSNotice of Results and Investor Presentation
6th Nov 20237:00 amRNSTrading Update
24th Oct 202310:16 amRNSHolding(s) in Company
9th Oct 20239:40 amRNSGrant of Options and Related Party Transaction
19th Sep 20232:35 pmRNSPlacing and Subscription, PDMR Dealing and TVR
13th Sep 202312:58 pmRNSHolding(s) in Company
31st Aug 20237:00 amRNSHolding(s) in Company
24th Aug 20236:09 pmRNSHolding(s) in Company
24th Aug 20236:05 pmRNSHolding(s) in Company
21st Aug 20231:20 pmRNSHolding(s) in Company
21st Aug 20231:17 pmRNSHolding(s) in Company
17th Aug 202312:47 pmRNSResult of General Meeting
17th Aug 20237:00 amRNSContract wins
15th Aug 20235:43 pmRNSTR-1
15th Aug 20235:40 pmRNSTR-1
2nd Aug 20233:41 pmRNSHolding(s) in Company
2nd Aug 20233:38 pmRNSHolding(s) in Company
31st Jul 20239:04 amRNSForm 8.5 (EPT/RI)
31st Jul 20237:01 amRNSUpdate on Strategic Review and Formal Sale Process
31st Jul 20237:00 amRNSFundraise, Proposed Board Changes, RPT, GM Notice
28th Jul 20238:57 amRNSForm 8.5 (EPT/RI)
27th Jul 20239:36 amRNSForm 8.5 (EPT/RI) - Aptamer Group PLC
26th Jul 202310:57 amRNSResponse to Speculation, Strategic Review, Update
7th Jul 20237:00 amRNSContract Wins
4th Jul 20237:00 amRNSTrading Update
14th Jun 202312:16 pmRNSResponse to Share Price Movement
14th Jun 20237:00 amRNSAptamer & Neuro-Bio to develop Alzheimer’s test
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.